Grants and Contracts Details
| Status | Finished |
|---|---|
| Effective start/end date | 4/29/16 → 10/20/20 |
Funding
- Genentech Inc: $202,883.00
15-LUN-100-HR: A Phase III, Open-label, Randomized Study of Atezolizumab (MPDL3280A, ANTI-PD-L1 Antibody) in Combination With Carboplatin or Cisplatin + Pemetrexed In Patients Who Are Chemotherapy-Naive and Have Stage IV Non-Squamous
- Arnold, Susanne (PI)
- Anthony, Lowell (CoI)
- Thind, Ravneet (CoI)
- Villano, PhD, John (CoI)
- Hosein, Peter (Former CoI)